Oncology

Key Disruptors in The Multiple Myeloma Landscape: 2020 and Beyond

Accelerated innovation in drug design and development is providing diverse treatment options for cancer patients, including hematological malignancies, like multiple myeloma. However, innovation has complicated physicians’ therapy selection and decision making, including how best to sequence treatment across lines of therapy. Thereby contributing to an unmet need for indications like multiple myeloma, that are typically […]

First-in-class Tazverik launched for rare sarcoma, wider use will drive market value

Epizyme’s first-in-class EZH2 (enhancer of zeste homolog 2) inhibitor Tazverik (tazemetostat) has become the first therapy to be made available in the U.S. for the treatment of epithelioid sarcoma (ES), a rare soft tissue tumor with a significant unmet need.1,2,3 The drug was granted accelerated approval in January 2020 for the treatment of patients aged […]

ASH 2019: How Can CAR T-cell Developers Ensure Differentiation in NHL?

Commercial availability of two anti-CD19 CAR T-cell therapies (Kite/Gilead’s Yescarta and Novartis’ Kymriah) has revolutionized treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). To date, the efficacy of these novel therapies has been impressive, but severe side effects, logistical hurdles, and reimbursement delays have hindered delivery of these personalized treatments […]

Diverse approaches in immuno-oncology

A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting this month in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of […]

Results from PARP Inhibitor Trials Point to Drastic Changes for Ovarian Cancer Management

What ESMO 2019 announcements mean for the future of the ovarian cancer market and patient care PARP inhibitors have shown extremely encouraging data that could help pave the way for an entirely new treatment algorithm in ovarian cancer. These agents have given patients the opportunity for more effective treatments in the frontline and recurrent settings. […]

Malignant Melanoma – Is Cure a Possibility?

5-year survival data from CheckMate-067 trial released at ESMO 2019, highlighting the efficacy of immunotherapy in the treatment of malignant melanoma, regardless of BRAF status In the last decade, immunotherapy has revolutionised the treatment of malignant melanoma. Before 2011, no effective treatment was available for this chemotherapy-resistant cancer, and patients with metastatic disease (stage IV) […]

UnitedHealth Prefers Oncology Biosimilars Over Roche’s Herceptin, Avastin

Effective Oct. 1, 2019, UnitedHealthcare will be adding utilization criteria for Avastin and Herceptin for members under commercial and community health plans. United is adding a requirement that patients use the biosimilars Kanjinti and Mvasi prior to using the original cancer drugs. Mvasi (bevacizumab-awwb) is the first FDA-approved biosimilar to Avastin (bevacizumab) for the treatment of […]

ASCO 2019: The future of Keytruda plus chemo combination therapy

Checkpoint inhibitor combination strategies remains a focus of development, but chemo combos are not a slam dunk for every indication. As the 40,000 attendees of this year’s ASCO conference relinquish their hold of the windy city, oncology experts worldwide begin contemplating the wealth of new or expanded data which was presented, and how it might […]

Oncology, dermatology, hematology pace Q1 biopharma licensing

During the first quarter of 2019, Cortellis Deals Intelligence registered 1,023 new deals (excluding mergers & acquisitions) as part of its ongoing coverage of licensing activity in the life sciences sector, a minor decrease of 0.6% from 1,029 in Q1 a year ago. The total disclosed deal value rose to $44.9 billion, a 26.8% rise […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends,” was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]